Status: Recruiting
LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
This is a phase III, Multicenter, Randomized study, evaluating the efficacy and Safety of LM-108(an Anti-CCR8 mAb) in combination With Toripalimab Versus Paclitaxel Injection in subjects with CCR8-Positive locally advanced or metastatic Gastric Cancer and Gastroesophageal Junction Adenocarcinoma.
Participants needed: 400
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: LaNova Medicines LimitedUpdated: May 11, 2026Locations: 1
Eligibility criteria
Individuals who are willing to participate in the study and sign the informed co... [+11]
Received treatment targeting the same target or other drugs acting on regulatory... [+12]